CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers. Irv Gotti, Music Executive Behind Ja Rule ...

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $62 from $60 and keeps an Equal Weight rating on the shares. While ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...